AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21699953 — intervention group
Group type: EXPERIMENTAL
Intervention: P. ginseng extract (2g/day) for 4 weeks
Number of subjects: 82
Study 21699953 — intervention group
Group type: EXPERIMENTAL
Intervention: P. ginseng extract (1g/day) for 4 weeks
Number of subjects: 82
Study 21699953 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 82
Study 18259825 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy for pancreatic cancer
Number of subjects: 0
Study 18259825 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy for pancreatic cancer
Number of subjects: 0
Study 16649857 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse groups (racially heterogeneous)
Number of subjects: 0
Study 16649857 — intervention group
Group type: COMPARATOR
Intervention: All-White groups
Number of subjects: 0
Study 16649857 — intervention group
Group type: EXPERIMENTAL
Intervention: Whites in diverse groups
Number of subjects: 0
Study 16649857 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to pretrial jury selection questions about racism
Number of subjects: 0
Study 16649857 — intervention group
Group type: COMPARATOR
Intervention: No exposure to pretrial jury selection questions about racism
Number of subjects: 0
Study 14635236 — intervention group
Group type: COMPARATOR
Intervention: Women textile workers
Number of subjects: 267400
Study 10959482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (100-150 mg daily)
Number of subjects: 41
Study 8851242 — intervention group
Group type: EXPERIMENTAL
Intervention: Task group (counting longer tones)
Number of subjects: 0
Study 8851242 — intervention group
Group type: COMPARATOR
Intervention: No-task group (no instructed task)
Number of subjects: 0
Study 1284331 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms levothyroxine per day (Group A)
Number of subjects: 166
Study 1284331 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms iodine per day (Group B)
Number of subjects: 166
Study 1284331 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms levothyroxine and 200 micrograms iodine per day (Group C)
Number of subjects: 166
Study 2861759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (80 micrograms/kg iv)
Number of subjects: 16
Study 2861759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (80 micrograms/kg iv) in patients pretreated with beta-receptor blockers and receiving fentanyl (7 micrograms/kg)
Number of subjects: 16
Study 2861759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (80 micrograms/kg iv) in patients not on preoperative beta-receptor blocker medication
Number of subjects: 16
Study 2861759 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (70 micrograms/kg iv)
Number of subjects: 16
Study 31851172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortexin (10 days, once daily intramuscularly)
Number of subjects: 54
Study 31851172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacotherapy)
Number of subjects: 54
Study 29464980 — intervention group
Group type: EXPERIMENTAL
Intervention: TCA 33%
Number of subjects: 90
Study 29464980 — intervention group
Group type: COMPARATOR
Intervention: Vaseline (placebo)
Number of subjects: 90
Study 26988134 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance intervention
Number of subjects: 66
Study 26988134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring intervention
Number of subjects: 66
Study 26988134 — intervention group
Group type: COMPARATOR
Intervention: Neutral comparison condition
Number of subjects: 66
Study 25026806 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptol (3 tablets, 1500 mg daily)
Number of subjects: 80
Study 25026806 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (disintoxication therapy, prednisolone 30‐60 mg/day, antihistamines, phototherapy, topical steroids, topical emollients)
Number of subjects: 80
Study 22494062 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel(TM) laryngeal mask airway with sevoflurane
Number of subjects: 47
Study 22494062 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel(TM) laryngeal mask airway with desflurane
Number of subjects: 47
Study 22494062 — intervention group
Group type: COMPARATOR
Intervention: Control group (preoperative measurement)
Number of subjects: 47
Study 22494062 — intervention group
Group type: COMPARATOR
Intervention: Comparison between sevoflurane and desflurane groups
Number of subjects: 47
Study 21038653 — intervention group
Group type: EXPERIMENTAL
Intervention: BAI with oleum fructus bruceae (OFB) + chemotherapeutic agents (CTA)
Number of subjects: 103
Study 21038653 — intervention group
Group type: COMPARATOR
Intervention: BAI with chemotherapeutic agents (CTA) alone
Number of subjects: 103
Study 17925417 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged exercise training
Number of subjects: 18
Study 17925417 — intervention group
Group type: COMPARATOR
Intervention: Two-legged exercise training
Number of subjects: 18
Study 16398771 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 microg) and intravenous oxytocin (10 IU/hour)
Number of subjects: 173
Study 16398771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 12924516 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoSet (Resmed)
Number of subjects: 50
Study 12924516 — intervention group
Group type: COMPARATOR
Intervention: SOMNOsmart (Weinmann)
Number of subjects: 50
Study 11076823 — intervention group
Group type: EXPERIMENTAL
Intervention: ICUS-guided provisional stenting
Number of subjects: 291
Study 11076823 — intervention group
Group type: COMPARATOR
Intervention: Standard angiographic guidance
Number of subjects: 291
Study 8794822 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg QD)
Number of subjects: 20
Study 8794822 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (95 mg QD)
Number of subjects: 20
Study 1310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 60 micrograms kg‐1
Number of subjects: 60
Study 1310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 80 micrograms kg‐1
Number of subjects: 60
Study 1310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 100 micrograms kg‐1
Number of subjects: 60
Study 1310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (in Groups B and C)
Number of subjects: 60
Study 1310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine and edrophonium (in Subgroup A)
Number of subjects: 60
Study 6391153 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg SAMe per os tid during oral contraceptive treatment
Number of subjects: 6
Study 6391153 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives containing 50 micrograms ethynylestradiol plus 250 micrograms d-norgestrel
Number of subjects: 6
Study 31079201 — intervention group
Group type: EXPERIMENTAL
Intervention: Three consecutive exercise days (3CON)
Number of subjects: 10
Study 31079201 — intervention group
Group type: COMPARATOR
Intervention: Single bout of exercise (SB)
Number of subjects: 10
Study 31079201 — intervention group
Group type: COMPARATOR
Intervention: Three alternate exercise days (3ALT)
Number of subjects: 10
Study 31079201 — intervention group
Group type: COMPARATOR
Intervention: No exercise control (R)
Number of subjects: 10
Study 29354952 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection at Zusanli (ST 36)
Number of subjects: 60
Study 29354952 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl at Zusanli (ST 36)
Number of subjects: 60
Study 25250670 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 21
Study 25250670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23424017 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone
Number of subjects: 862
Study 23424017 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 862
Study 21570271 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g brewer's yeast (42 μg Cr) daily for 3 months
Number of subjects: 40
Study 19634546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 100 microg/kg 15 minutes before induction
Number of subjects: 113
Study 19634546 — intervention group
Group type: COMPARATOR
Intervention: Placebo 15 minutes before induction
Number of subjects: 113
Study 16557601 — intervention group
Group type: EXPERIMENTAL
Intervention: Transulnar approach
Number of subjects: 431
Study 16557601 — intervention group
Group type: COMPARATOR
Intervention: Transradial approach
Number of subjects: 431
Study 14960109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorized thumb with piezoresistive force sensors
Number of subjects: 7
Study 10856732 — intervention group
Group type: EXPERIMENTAL
Intervention: eprosartan (540+/‐96 mg/day)
Number of subjects: 20
Study 10856732 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 8612032 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school course
Number of subjects: 494
Study 8612032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 494
Study 1588148 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide vaccine
Number of subjects: 58000
Study 1588148 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine (polysaccharide conjugated to diphtheria toxoid)
Number of subjects: 58000
Study 1588148 — intervention group
Group type: COMPARATOR
Intervention: PRP-D vaccine
Number of subjects: 58000
Study 1588148 — intervention group
Group type: COMPARATOR
Intervention: HbOC vaccine (oligosaccharide conjugated to CRM197 protein)
Number of subjects: 58000
Study 6748780 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician interview
Number of subjects: 30
Study 6748780 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient interview
Number of subjects: 30
Study 6748780 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped observation
Number of subjects: 30
Study 6748780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart audit
Number of subjects: 30
Study 29027352 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous donor hypothermia (core body temperature <36°C)
Number of subjects: 0
Study 29027352 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor dopamine treatment
Number of subjects: 0
Study 25702786 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU of vitamin D3 per week
Number of subjects: 484
Study 25702786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study 24737923 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory therapy after surgery
Number of subjects: 38
Study 24737923 — intervention group
Group type: COMPARATOR
Intervention: No anti-inflammatory therapy after surgery
Number of subjects: 38
Study 24417929 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin group (continued aspirin, discontinued clopidogrel at least 5 days before surgery)
Number of subjects: 480
Study 24417929 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel group (had both until 3 days before surgery)
Number of subjects: 480
Study 24417929 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued antiplatelet therapy 5 days before surgery)
Number of subjects: 480
Study 20497899 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutionalized children
Number of subjects: 117
Study 20497899 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 117
Study 18179713 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day) for bipolar mania
Number of subjects: 406
Study 18179713 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day) for schizophrenia
Number of subjects: 406
Study 16794788 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (5 mg twice per day, increased to maximum tolerated dose)
Number of subjects: 650
Study 16794788 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate (20 mg three times per day, increased to maximum tolerated dose)
Number of subjects: 650
Study 12584671 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat 40 mg
Number of subjects: 723
Study 12584671 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat 20 mg
Number of subjects: 723
Study 12584671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study 10637684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (methylphenidate or placebo)
Number of subjects: 81
Study 10637684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological treatment (parent groups: training or support)
Number of subjects: 81
Study 10637684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological and nonpharmacological treatments
Number of subjects: 81
Study 8546281 — intervention group
Group type: EXPERIMENTAL
Intervention: External high frequency oscillation at 1-5 Hz
Number of subjects: 20
Study 8546281 — intervention group
Group type: EXPERIMENTAL
Intervention: External high frequency oscillation
Number of subjects: 20
Study 8546281 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation
Number of subjects: 20
Study 1975189 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 32
Study 1975189 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 200 mg
Number of subjects: 32
Study 1975189 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 32
Study 1975189 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (100 mg and 200 mg)
Number of subjects: 32
Study 7270984 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol syrup
Number of subjects: 14
Study 7270984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31472678 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation + gluten-free diet (PRO-GFD)
Number of subjects: 120
Study 31472678 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation + gluten-free diet (PLA-GFD)
Number of subjects: 120
Study 31472678 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation + gluten-containing diet (PRO-GD)
Number of subjects: 120
Study 31472678 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation + gluten-containing diet (PLA-GD)
Number of subjects: 120
Study 28374907 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% (v/v) glycerine added to a reduced volume of soaking water
Number of subjects: 193
Study 28374907 — intervention group
Group type: COMPARATOR
Intervention: Control group (current skincare regimen)
Number of subjects: 193
Study 26708707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch community-based alcohol intervention
Number of subjects: 5700
Study 26708707 — intervention group
Group type: COMPARATOR
Intervention: Reference region (control)
Number of subjects: 5700
Study 24608079 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose intravenous methotrexate (MTX) 2.5 g/m
Number of subjects: 784
Study 24608079 — intervention group
Group type: COMPARATOR
Intervention: Standard dose intravenous methotrexate (MTX) 1 g/m
Number of subjects: 784
Study 24608079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside/asparaginase
Number of subjects: 784
Study 24608079 — intervention group
Group type: COMPARATOR
Intervention: Cytosine arabinoside/teniposide
Number of subjects: 784
Study 23012385 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous doripenem
Number of subjects: 12
Study 23012385 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous doripenem
Number of subjects: 12
Study 19281588 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 164
Study 19281588 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 164
Study 17804673 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-based blood pressure-lowering therapy
Number of subjects: 6105
Study 17804673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 15141263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg per rectum every 4 hours
Number of subjects: 42
Study 15141263 — intervention group
Group type: COMPARATOR
Intervention: Placebo per rectum every 4 hours
Number of subjects: 42
Study 12667363 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (Ca) 400 mg/d + vitamin D 200 IU/D (Control group)
Number of subjects: 92
Study 12667363 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V 1.0 mg/d + MPA 2 mg/d + Ca 400 mg/d (Treatment group 1)
Number of subjects: 92
Study 12667363 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V 1.0 mg/d + MPA 2 mg/d + Ca 400 mg/d + vitamin D 200 IU/d (Treatment group 2)
Number of subjects: 92
Study 12667363 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V 1.5 mg/d + MPA 2 mg/d + Ca 400 mg/d + vitamin D 200 IU/d (Treatment group 3)
Number of subjects: 92
Study 10604697 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade percutaneous approach
Number of subjects: 60
Study 10604697 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde hot-wire balloon incision
Number of subjects: 60
Study 7818118 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of 1.5% lidocaine with epinephrine (1:200,000) IV
Number of subjects: 30
Study 7818118 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of normal saline IV
Number of subjects: 30
Study 1703451 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 and fluoro‐uracil 1000 mg/m2/d administered in continuous IV infusion for 96 h every 4 weeks (group 1)
Number of subjects: 113
Study 1703451 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 350 mg/m2 and fluoro‐uracil administered at the same dose every 3 weeks (group II)
Number of subjects: 113
Study 1703451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined therapy with carboplatin and fluoro‐uracil)
Number of subjects: 113
Study 1703451 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 113
Study 1703451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 1703451 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 113
Study 380347 — intervention group
Group type: EXPERIMENTAL
Intervention: cefamandole
Number of subjects: 120
Study 380347 — intervention group
Group type: EXPERIMENTAL
Intervention: cephalothin
Number of subjects: 120
Study 380347 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 31812686 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol
Number of subjects: 301
Study 31812686 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer
Number of subjects: 301
Study 31812686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 31812686 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulvovaginal symptom severity
Number of subjects: 301
Study 31812686 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms (PHQ-8)
Number of subjects: 301
Study 31812686 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent sexual activity
Number of subjects: 301
Study 31398376 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR)
Number of subjects: 218
Study 31398376 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum (AL)
Number of subjects: 218
Study 28446631 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced protein‐energy supplementation of 500 mL milk/d plus a 10‐μg vitamin B‐12 tablet/d (M+B‐12 group)
Number of subjects: 93
Study 28446631 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (500 mL/d) plus a placebo tablet (M+P group)
Number of subjects: 93
Study 28446631 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet alone (P group)
Number of subjects: 93
Study 25848883 — intervention group
Group type: EXPERIMENTAL
Intervention: HD bronchoscopy with surface- and tone enhancement technique (i-scan2)
Number of subjects: 29
Study 25848883 — intervention group
Group type: COMPARATOR
Intervention: Dual mode autofluorescence videobronchoscopy (AFB)
Number of subjects: 29
Study 25848883 — intervention group
Group type: EXPERIMENTAL
Intervention: AFB
Number of subjects: 29
Study 25848883 — intervention group
Group type: COMPARATOR
Intervention: White light bronchoscopy (WLB) and HD bronchoscopy
Number of subjects: 29
Study 25848883 — intervention group
Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 29
Study 25848883 — intervention group
Group type: EXPERIMENTAL
Intervention: HD bronchoscopy with i-scan
Number of subjects: 29
Study 23996419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 57
Study 23996419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol with lorazepam
Number of subjects: 57
Study 21181130 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cortisol (30 mg)
Number of subjects: 60
Study 21181130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20009074 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote magnetic catheter navigation (RMN)
Number of subjects: 90
Study 20009074 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual catheter ablation
Number of subjects: 90
Study 17978289 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (80 mg/m²/day for 4 weeks followed by 2 weeks off, for 1 year)
Number of subjects: 1059
Study 17978289 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 1059
Study 17978289 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 1059
Study 14604720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edged Sensar OptiEdge AR40e IOL (Allergan Surgical)
Number of subjects: 52
Study 14604720 — intervention group
Group type: COMPARATOR
Intervention: Round-edged Sensar AR40 IOL
Number of subjects: 52
Study 10773509 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3 micrograms/kg, 15 min before induction)
Number of subjects: 60
Study 10773509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8642820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator at 60% power output
Number of subjects: 6
Study 8642820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator at 80% power output
Number of subjects: 6